Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study.

Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study.

<p><strong>Aims</strong> Statins reduce LDL cholesterol (LDL-C) and the risk of vascular events, but it remains uncertain whether there is clinically relevant genetic variation in their efficacy. This study of 18 705 individuals aims to identify genetic variants related to the lipi...

ver descrição completa

Detalhes bibliográficos
Principais autores:	Hopewell, J, Parish, S, Offer, A, Link, E, Clarke, R, Lathrop, M, Armitage, J, Collins, R
Formato:	Journal article
Idioma:	English
Publicado em:	Oxford University Press 2013

Registros relacionados

Genetic variation in lipid response to statin therapy in 18,705 participants in the heart protection study
por: Hopewell, J, et al.
Publicado em: (2011)

No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study.
por: Hopewell, J, et al.
Publicado em: (2011)

Lipoprotein(a) Genetic Variants Associated With Risk of Atherothrombotic Disease in 14,465 Participants From the Heart Protection Study
por: Hopewell, J, et al.
Publicado em: (2010)

Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom
por: Hopewell, JC, et al.
Publicado em: (2020)

Lipoprotein(a) genetic variants associated with coronary and peripheral vascular disease but not with stroke risk in the Heart Protection Study.
por: Hopewell, J, et al.
Publicado em: (2011)

Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study.
por: Parish, S, et al.
Publicado em: (2012)

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.
por: Collins, R, et al.
Publicado em: (2003)

No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study.
por: Hopewell, J, et al.
Publicado em: (2011)

Environmental and genetic risk factors for myopathy in Chinese participants from HPS2-THRIVE
por: Hopewell, J, et al.
Publicado em: (2012)

No Impact of KIF6 Genotype on Vascular Risk or Statin Benefit in the Heart Protection Study
por: Hopewell, J, et al.
Publicado em: (2009)

Regarding "Does simvastatin save lives; If so, when and in whom?" - Reply
por: Bulbulia, R, et al.
Publicado em: (2008)

Safety of long-term simvastatin discontinuation Reply
por: Bulbulia, R, et al.
Publicado em: (2012)

Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions.
por: Collins, R, et al.
Publicado em: (2004)

Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people.
por: Armitage, J, et al.
Publicado em: (2009)

Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals.
por: Mihaylova, B, et al.
Publicado em: (2005)

Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people.
por: Mihaylova, B, et al.
Publicado em: (2006)

Heart Protection Study - Reply
por: Collins, R, et al.
Publicado em: (2003)

The Impact of Genetic Variants Related to LDL-cholesterol on Risk of Ischemic Stroke and Coronary Heart Disease
por: Hopewell, J, et al.
Publicado em: (2012)

C-reactive protein in the Heart Protection Study - Authors' reply
por: Emberson, J, et al.
Publicado em: (2011)

Absence of effects of prolonged simvastatin therapy on nocturnal sleep in a large randomized placebo-controlled study. Oxford Cholesterol Study Group.
por: Keech, A, et al.
Publicado em: (1996)

MRC/BHF Heart Protection Study - Reply
por: Collins, R, et al.
Publicado em: (2002)

New analyses of Heart Protection Study - Reply
por: Collins, R, et al.
Publicado em: (2004)

Economic analysis of simvastatin in 20,536 people at different levels of vascular disease risk based on US costs: Randomised placebo-controlled trial
por: Mihaylova, B, et al.
Publicado em: (2005)

Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial.
por: Bulbulia, R, et al.
Publicado em: (2011)

C-reactive protein in the Heart Protection Study Reply
por: Emberson, J, et al.
Publicado em: (2011)

Comments on the MRC/BHF Heart Protection Study - Authors' reply
por: Collins, R, et al.
Publicado em: (2003)

Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial.
por: Armitage, J, et al.
Publicado em: (2010)

Economic evaluation of the Heart Protection Study
por: Briggs, A, et al.
Publicado em: (2003)

SLCO1B1 variants and statin-induced myopathy--a genomewide study.
por: Link, E, et al.
Publicado em: (2008)

Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes
por: Hanson Mary E, et al.
Publicado em: (2010-07-01)

MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial
por: Collins, R, et al.
Publicado em: (2002)

N-BNP and vascular disease among 20,536 patients in the MRC/BHF Heart Protection Study
por: Emberson, J, et al.
Publicado em: (2005)

Ezetimibe/simvastatin (vytorin) in heart and renal protection: The SHARP trial
por: Alexander, W, et al.
Publicado em: (2011)

MRC/BHF heart protection study (HPS): Mortality, cancer incidence and major vascular events during 4 years post-trial follow-up of HPS
por: Bulbulia, R, et al.
Publicado em: (2007)

Common Genetic Variants Associated With Higher Lp(a) Concentrations and Increased Risk of Coronary Heart Disease
por: Clarke, R, et al.
Publicado em: (2009)

AGW 705 - ADVANCED MARKETING SEMINAR APRIL 08.
por: PPP, Pusat Pengajian Pengurusan
Publicado em: (2008)

Impact of apolipoprotein(a) isoform size on lipoprotein(a) lowering in the HPS2-THRIVE study
por: Parish, S, et al.
Publicado em: (2018)

The MRC/BHF Heart Protection Study: preliminary results.
por: Collins, R, et al.
Publicado em: (2002)

N-terminal pro-B-type natriuretic peptide and vascular disease among 20,536 patients in the MRC/BHF heart protection study
por: Emberson, J, et al.
Publicado em: (2005)

Impact of lipoprotein(a) levels and apolipoprotein(a) isoform size on risk of coronary heart disease
por: Hopewell, J, et al.
Publicado em: (2014)